» Articles » PMID: 21151173

Wnt/β-catenin Activation Promotes Prostate Tumor Progression in a Mouse Model

Overview
Journal Oncogene
Date 2010 Dec 15
PMID 21151173
Citations 81
Authors
Affiliations
Soon will be listed here.
Abstract

Our previous studies have found that activation of Wnt/β-catenin signaling resulted in mouse prostatic intraepithelial neoplasia (mPIN). In the large probasin promoter directed SV40-large T-antigen (LPB-Tag) expressing mouse prostate, mPIN forms with rare areas of adenocarcinoma. Combining expression of both Wnt-signaling and Tag expression in the mouse prostate, we have studied the role of Wnt/β-catenin signaling in the progression from mPIN to adenocarcinoma. Our results show that the prostates of mice expressing Tag alone or nuclear β-catenin alone developed mPIN, whereas the activation of both Tag and the Wnt/β-catenin pathway resulted in invasive prostate adenocarcinoma. Furthermore, Foxa2, a forkhead transcription factor, was induced by active Wnt/β-catenin signaling, and the expression of Foxa2 was associated with the invasive phenotype in the primary prostate cancer. In the LPB-Tag/dominant active (DA) β-catenin prostates, MMP7, a Wnt/β-catenin target gene, was upregulated. Furthermore, we also assessed AR and AR signaling pathway in these LPB-Tag/DA β-catenin mice. Although β-catenin is a well-known AR co-activator in vitro, our study provides strong in vivo evidences indicating that both AR protein and the AR pathway were downregulated in the prostate of LPB-Tag/DA β-catenin mice. Histological analysis shows that prostate sections derived from the LPB-Tag/DA β-catenin mice display neuroendocrine differentiation (NED), but NE cancer does not develop. Together, our findings indicate that Wnt/β-catenin signaling has an important role in the progression of mPIN to prostate adenocarcinoma.

Citing Articles

Phospholipase C Beta 2 as a Key Regulator of Tumor Progression and Epithelial-Mesenchymal Transition via PI3K/AKT Signaling in Renal Cell Carcinoma.

Wang S, Xie D, Yue H, Li G, Jiang B, Gao Y Biomedicines. 2025; 13(2).

PMID: 40002717 PMC: 11853330. DOI: 10.3390/biomedicines13020304.


Diverse landscape of genetically engineered mouse models: Genomic and molecular insights into prostate cancer.

Kaushal J, Takkar S, Batra S, Siddiqui J Cancer Lett. 2024; 593:216954.

PMID: 38735382 PMC: 11799897. DOI: 10.1016/j.canlet.2024.216954.


FOXA2 Suppression by TRIM36 Exerts Anti-Tumor Role in Colorectal Cancer Via Inducing NRF2/GPX4-Regulated Ferroptosis.

Liu X, Yan C, Chang C, Meng F, Shen W, Wang S Adv Sci (Weinh). 2023; 10(35):e2304521.

PMID: 37875418 PMC: 10724393. DOI: 10.1002/advs.202304521.


Dissecting the effects of androgen deprivation therapy on cadherin switching in advanced prostate cancer: A molecular perspective.

Varisli L, Tolan V, Cen J, Vlahopoulos S, Cen O Oncol Res. 2023; 30(3):137-155.

PMID: 37305018 PMC: 10208071. DOI: 10.32604/or.2022.026074.


Pretreatment of prostate cancer cells with salinomycin and Wnt inhibitor increases the efficacy of cabazitaxel by inducing apoptosis and decreasing cancer stem cells.

Serttas R, Erdogan S Med Oncol. 2023; 40(7):194.

PMID: 37264204 DOI: 10.1007/s12032-023-02062-1.


References
1.
Qi J, Nakayama K, Cardiff R, Borowsky A, Kaul K, Williams R . Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell. 2010; 18(1):23-38. PMC: 2919332. DOI: 10.1016/j.ccr.2010.05.024. View

2.
Gupta A, Wang Y, Browne C, Kim S, Case T, Paul M . Neuroendocrine differentiation in the 12T-10 transgenic prostate mouse model mimics endocrine differentiation of pancreatic beta cells. Prostate. 2007; 68(1):50-60. DOI: 10.1002/pros.20650. View

3.
Mirosevich J, Gao N, Matusik R . Expression of Foxa transcription factors in the developing and adult murine prostate. Prostate. 2004; 62(4):339-52. DOI: 10.1002/pros.20131. View

4.
Huang D, Du X . Crosstalk between tumor cells and microenvironment via Wnt pathway in colorectal cancer dissemination. World J Gastroenterol. 2008; 14(12):1823-7. PMC: 2700405. DOI: 10.3748/wjg.14.1823. View

5.
De La Taille A, Rubin M, Chen M, Vacherot F, Gil-Diez de Medina S, Burchardt M . Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. Clin Cancer Res. 2003; 9(5):1801-7. View